Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Clinical trial NCT07137481 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07137481
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-02-28
- Primary completion
- 2030-07-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.